Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy

(2012) Narendra Chirmule et al.   AAPS Journal

Immunogenicity of biological therapeutics

(2012) Charlotte Krieckaert et al.   CURRENT OPINION IN RHEUMATOLOGY

Prevention and prediction of inhibitor risk

(2012) J. ASTERMARK   HAEMOPHILIA

IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients

(2012) Pauline A. van Schouwenburg et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

(2011) A Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: A case series and cohort study

(2011) L. A. Korswagen et al.   ARTHRITIS AND RHEUMATISM

Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate

(2011) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Requirements for immune recognition and processing of factor VIII by antigen-presenting cells

(2011) Simon D. van Haren et al.   BLOOD REVIEWS

Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo

(2011) Leonard Moise et al.   CLINICAL IMMUNOLOGY

The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site

(2011) M M Stickler et al.   GENES AND IMMUNITY

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Differential effect of drug interference in immunogenicity assays

(2011) Margreet H. Hart et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Unresolved issues in biologic therapy for rheumatoid arthritis

(2011) Ronald F. van Vollenhoven   Nature Reviews Rheumatology

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

(2011) D. Pascual-Salcedo et al.   RHEUMATOLOGY

Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study

(2011) Geertje M Bartelds et al.   ARTHRITIS RESEARCH & THERAPY

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

(2010) A. Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Meeting report on protein particles and immunogenicity of therapeutic proteins: Filling in the gaps in risk evaluation and mitigation

(2010) John Carpenter et al.   BIOLOGICALS

Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-α) during therapy for chronic hepatitis C

(2010) G. GIANNELLI et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

(2010) S. Ben-Horin et al.   GUT

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients

(2010) Pauline A. van Schouwenburg et al.   JOURNAL OF IMMUNOLOGICAL METHODS

A Novel Strategy To Reduce the Immunogenicity of Biological Therapies

(2010) J. Somerfield et al.   JOURNAL OF IMMUNOLOGY

Exploring the Binding Sites of Anti-Infliximab Antibodies in Pediatric Patients With Rheumatic Diseases Treated With Infliximab

(2010) Miha Kosmač et al.   PEDIATRIC RESEARCH

Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions

(2009) A. Vultaggio et al.   ALLERGY

Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms

(2009) G. M. Bartelds et al.   ARTHRITIS AND RHEUMATISM

Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells

(2009) Hernandez M. Silva et al.   IMMUNOLOGY LETTERS

IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab

(2009) Charlotte Magdelaine-Beuzelin et al.   Pharmacogenetics and Genomics

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

(2008) J Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

(2008) R Fleischmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95

(2008) Annett M. Jacobi et al.   ARTHRITIS AND RHEUMATISM

Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurement

(2008) Lucien Aarden et al.   CURRENT OPINION IN IMMUNOLOGY

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

(2008) Eugen Koren et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

(2008) Nobuyuki Miyasaka et al.   Modern Rheumatology

Glycosylation of Recombinant Antibody Therapeutics

(2005) Royston Jefferis   BIOTECHNOLOGY PROGRESS